K101456 SEP 0 8 2010

510(k) Summary – Calibrator for Automated Systems (C.f.a.s.) and C.f.a.s. CK-MB

Introduction

Roche Diagnostics Corporation hereby submits this 510(k) to provide notification of modifications to our Calibrator for automated systems (C.f.a.s.) and C.f.a.s. CK-MB.

- 1. C.f.a.s. was originally cleared for use in K990460, then modified in K033501 and K062319.
- 2. C.f.a.s. CK-MB was originally cleared for use in K003158.

Modifications to these devices include changing common source materials for three analytes

- Human recombinant Gamma-glutamyltransferase (γ GT) will replace porcine kidney γ GT in C.f.a.s.
- Human recombinant Aspartate aminotransferase (AST) will replace porcine heart AST in C.f.a.s.
- Human recombinant Creatine Kinase Isoenzyme MB (CK-MB) will replace porcine brain Creatine Kinase Isoenzyme BB (CK-BB) in C.f.a.s. CK-MB.

Submitter name, address, contact

Roche Diagnostics 9115 Hague Rd. PO Box 50416

Indianapolis, IN 46250 Phone: (317) 521-3380 Fax: (317) 521-2324

Contact Person: Susan Hollandbeck

Date prepared: June 16, 2010

Device names

Proprietary names:

- 1. Roche Diagnostics Calibrator for automated systems
- 2. Roche Diagnostics Calibrator for automated systems CK-MB

Common names:

- 1. C.f.a.s.
- 2. C.f.a.s. CK-MB

Classification names:

- 1. Calibrator, Multi-analyte mixture
- 2. Calibrator, Secondary

Product Codes:

- 1. JIX
- 2. JIT

Device description

- 1. C.f.a.s. is for use in the calibration for automated Roche methods on Roche chemistry analyzers as specified in the enclosed value sheet. It is a lyophilized calibrator based on human serum.
- 2. C.f.a.s. CK-MB is for use in the calibration of Roche methods for the quantitative determination of the MB Isoenzyme of Creatine kinase on automated clinical chemistry analyzers. It is a lyophilized calibrator based on bovine serum albumin.

Intended use

- 1. Calibrator for automated systems (C.f.a.s.) is for use in the calibration for automated Roche methods on Roche chemistry analyzers as specified in the value sheets.
- 2. C.f.a.s. (Calibrator for automated systems) CK-MB is for use in the calibration of Roche methods for the quantitative determination of CK-MB on Roche clinical chemistry analyzers as specified in the value sheets.

Predicate devices

We claim substantial equivalence to the following currently marketed devices.

- 1. Calibrator for automated systems cleared in K062319.
- 2. Calibrator for automated systems CK-MB cleared in K003158.

Substantial equivalence

Tables 1 and 2 compare the features of the modified devices with their predicate devices. The first is a comparison of C.f.a.s.; the second is a comparison for C.f.a.s. CK-MB.

Table 1: Comparison of C.f.a.s.

Feature	C.f.a.s	C.f.a.s. K062319
- Cature	(Modified Device)	(Predicate Device)
Intended Use	Calibrator for automated systems (C.f.a.s.) is for use in the calibration of quantitative Roche methods on Roche clinical chemistry analyzers as specified in the value sheets.	Calibrator for automated systems (C.f.a.s) is for use in the calibration of quantitative Roche methods on Roche clinical chemistry analyzers as specified in the lot specific value sheet.
Format	Lyophilized	Same
Stability	Lyophilized calibrator 2 to 8 °C until expiration date Reconstituted calibrator 15 to 25 °C for 8 hours 2 to 8 °C for 2 days 15 to -25 °C for 4 weeks (when frozen once) Total Bilirubin in reconstituted calibrator when stored protected from light 15 to 25 °C for 6 hours 2 to 8 °C for 1 day 15 to -25 °C for 2 weeks (when frozen once) Direct Bilirubin in reconstituted calibrator when stored protected from light 15 to 25 °C for 3 hours 2 to 8 °C for 8 hours 2 to 8 °C for 8 hours 15 to -25 °C for 2 weeks (when frozen once)	Same
Levels	Single level	Same
Reagent Composition	Lyophilized human serum with chemical additives and material of biological origin	Same

Substantial equivalence (continued)

Table 1, continued...

Feature	C.f.a.s	C.f.a.s. K062319	
	(Modified Device)	(Predicate Device)	
	Traceability for each constituent is described in the reagent system instructions for use.	Same	
Traceability	Additional Reference Materials 1. SRM 909b and SRM 956 for Calcium 2. SRM 929 and SRM 956 for Magnesium 3. SRM 914 and SRM 967 for Creatinine Jaffe 4. SRM 909b (IDMS) and SRM 967 for Creatinine Plus 5. SRM 909b (IDMS) and SRM 1951 for Triglycerides GB Reference Material Name Changes 1. ERM DA470k for Albumin Plus 2. Primary Reference Material – USP for Salicylate	Reference Materials 1. SRM 909b for Calcium 2. SRM 929 for Magnesium 3. SRM 914 for Creatinine Jaffe 4. SRM 909b (IDMS) for Creatinine Plus 5. SRM 909b (IDMS) for Triglycerides GB Reference Material Names 1. CRM 470 for Albumin Plus 2. Primary Reference Material for Salicylate	
Value Assignment	Reference Method Publication Update 1. IFCC (2002), Manual for ALT 2. IFCC (2002), Manual for AST 3. IFCC (2002), Manual for CK 4. IFCC (2002), Manual for LD Values to new lots are assigned by running them as samples after calibrating the system with a previously assigned C.f.a.s. lot. Values are verified by using reference	Reference Method Publications 1. IFCC (1985), Manual for ALT 2. IFCC (1985), Manual for AST 3. IFCC (1991), Manual for CK 4. IFCC (1994), Manual for LD Same	
	material, Master lot C.f.a.s., and previously assigned lots of C.f.a.s.		
Source Material	 Human recombinant γGT Human recombinant AST 	 Porcine kidney γGT Porcine heart AST 	

Table 2: Comparison of C.f.a.s. CK-MB

Feature	C.f.a.s. CK-MB	C.f.a.s. CK-MB K003158
reature	(Modified Device)	(Predicate Device)
Intended Use	C.f.a.s. (Calibrator for automated systems) CK-MB is for use in the calibration of Roche methods for the quantitative determination of CK-MB on Roche clinical chemistry analyzers as specified in the value sheets.	C.f.a.s. (Calibrator for automated systems) CK-MB is for use in the calibration of Roche methods for the quantitative determination of CK-MB on automated clinical chemistry analyzers.
Format	Lyophilized	Same
	Lyophilized calibrator 2 to 8 °C until expiration date	Lyophilized calibrator • same
Stability	Reconstituted calibrator 15 to 25 °C for 24 hours 2 to 8 °C for 2 days 15 to -25 °C for 4 weeks (when frozen once)	Reconstituted calibrator 15 to 25 °C for 24 hours 2 to 8 °C for 2 days 20 °C for 1 month (when frozen once)
Levels	Single level	Same
Reagent Composition	Lyophilized calibrator based on bovine scrum albumin with chemical additives and material of biological origin.	Same
Traceability	Traceability for each constituent is described in the reagent system instructions for use.	Same
Value Assignment	Values to new lots are assigned by running them as samples after calibrating the system with a previously assigned C.f.a.s. CK-MB lot. Values are verified by using reference material, Master lot C.f.a.s CK-MB, and previously assigned lots of C.f.a.s. CK-MB.	Same
Source material	Human recombinant CK-MB Human CK-MM	Porcine brain CK-BB Human CK-MM

Constituents

Tables 3 and 4 catalog the constituent analytes and their biological source for both the modified and predicate devices. Table 3 summarizes C.f.a.s., a multi-analyte calibrator. For the modified C.f.a.s., the source material changes for two analytes, AST and γGT.

Table 3: Constituents of C.f.a.s.

(C.f.a.s Modified Device)	C.f.a.s. K06 (Predicate De	
Analyte	Source	Analyte	Source
ALT/ALAT	Porcine heart	ALT/ALAT	Same
AST/ASAT	Human, recombinant	AST/ASAT	Porcine heart
Albumin	Bovine plasma	Albumin	Same
Alkaline phosphatase	Human placenta (recombinant)	Alkaline phosphatase	Same
Amylase, total	Porcine pancreas	Amylase, total	Same
Amylase, pancreatic	Porcine pancreas	Amylase, pancreatic	Same
Bilirubin, direct	Endogenous and/or chemical additive	Bilirubin, direct	Same
Bilirubin, total	Endogenous and/or chemical additive	Bilirubin, total	Same
Calcium	Endogenous and/or chemical additive	Calcium	Same
Cholesterol	Bovine plasma	Cholesterol	Same
Cholinesterase	Human serum	Cholinesterase	Same
Creatine kinase	Rabbit muscle	Creatine kinase	Same
Creatinine	Endogenous and/or chemical additive	Creatinine	Same
γGT	Human, recombinant	γGT	Porcine kidney
Glucose	Endogenous and/or chemical additive	Glucose	Same
Iron	Endogenous and/or chemical additive	Iron	Same
· Lactate	Endogenous and/or chemical additive	Lactate	Same
LD (LDH)	Porcine heart	LD (LDH)	Same
Lipase	Human pancreas (recombinant)	Lipase	Same
Lithium ·	Chemical additive	N/A ^I	
Magnesium	Endogenous and/or chemical additive	Magnesium	Same
Phosphorus	Endogenous and/or chemical additive	Phosphorus	Same
Salicylate	Chemical additive	Salicylate	Same
Total Protein	Endogenous and/or chemical additive	Total Protein	Same
Triglycerides	Chicken egg yolk	Triglycerides	Same
UIBC	Endogenous and/or chemical additive	UIBC	Same
Urea/BUN	Endogenous and/or chemical additive	Urea	Same
Uric Acid	Endogenous and/or chemical additive	Uric Acid	Same

 $^{^{1}}$ C.f.a.s. was cleared as the calibrator in the Lithium test system in K063684. The source for lithium is the same.

Constituents (continued)

Table 4 summarizes C.f.a.s CK-MB. It is a single analyte calibrator that contains two Creatine kinase Isoenzyme sources; CK-MB Isoenzyme is the detected analyte in the test system. For the modified C.f.a.s. CK-MB, the source material changes for one of the two CK Isoenzyme biological additives.

Table 4: Constituents of C.f.a.s. CK-MB

C.f.a.s. CK-MB (Modified Device)		C.f.a.s. CK-MB K003158 (Predicate Device)	
Analyte	Source	Analyte	Source
CK-MB Isoenzyme	Human recombinant CK-MB Isoenzyme Human CK-MM Isoenzyme	CK-MB Isoenzyme	 Porcine brain CK-BB Isoenzyme Human CK-MM Isoenzyme







Roche Diagnostics c/o Susan Hollandbeck Regulatory Affairs Consultant 9115 Hague Road, P.O. Box 50416 Indianapolis, IN, 46250-0416 Food & Drug Administration 10903 New Hampshire Avenue Building 66 Silver Spring, MD 20993

SEP 8 2010

Re: k101456

Trade Names: Calibrator for automated systems (C.f.a.s.)

Calibrator for automated systems CK-MB (C.f.a.s. CK-MB)

Regulation Number: 21 CFR §862.1150

Regulation Name: Calibrator, Multi-Analyte Mixture and Calibrator, Secondary

Regulatory Class: Class II Product Codes: JIX, JIT Dated: August 23, 2010 Received: August 24, 2010

Dear Mr. Hollandbeck:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed

predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of *In Vitro* Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Courtney C. Harper, Ph.D.

Director

Division of Chemistry and Toxicology

Office of *In Vitro* Diagnostic Device Evaluation and Safety

Center for Devices and Radiological Health

Enclosure

Indications for Use Form

K(D)456 SEP 0 8 2010

10(k) Number (if known): k 101456
Pevice Name:
Calibrator for automated systems (C.f.a.s.)
ndications for Use:
Calibrator for automated systems (C.f.a.s) is for use in the calibration of quantitative Roche methods on Roche clinical chemistry analyzers as specified in the value sheets.
Prescription Usex AND/OR Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
ivision Sign-Off ffice of In Vitro Diagnostic Device valuation and Safety
10(k) K101456

Indications for Use Form

510(k) Number (if known): K101456		K101456
Device Name:		SEP 0 8 2010
Calibrator for automated systems (C.f.a.s.)	CK-MB	
Indications for Use:		
C.f.a.s. (Calibrator for automated systems) Roche methods for the quantitative determ chemistry analyzers as specified in the value	ination of CK-MB on Roche of	
Duoganiutian IIIa	Over The Courter Her	
Prescription Usex AND/OR (Part 21 CFR 801 Subpart D)	Over-The-Counter Use(21 CFR 801 Subpart C)	
(PLEASE DO NOT WRITE BELOW THIS LIN OF NEEDEL		R PAGE
Concurrence of CDRH, Office of In Vitr	o Diagnostic Devices (OIVD)	· · ·
Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety		
510(k) K101456	•	